Overview
- 4 inspections across 4 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2024-11-21.
At a glance
Inspections
4
Sites
4
Observations
1
Career since
Jan 2019
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Nicolas Scheyer, MD | 21 Nov 2024 | Human Drugs | |
| Novo Nordisk A/S | 17 Nov 2023 | Human Drugs | |
| Karyopharm Therapeutics Inc. | 28 Feb 2020 | Human Drugs | |
| Jaroslaw Niebrzydowski | 25 Jan 2019 | Human Drugs |
Sites inspected
Nicolas Scheyer, MDVandouvre-Les-Nancy, France1 insp.
Novo Nordisk A/SSoborg, Denmark1 insp.
Karyopharm Therapeutics Inc.Newton, United States1 insp.
Jaroslaw NiebrzydowskiGdynia, Poland1 insp.
Co-investigators
Investigators who share inspections with this person.
Theressa B Smith1 shared
Tawny L Colling1 shared
Lakecha N Lewis1 shared
Richard W Berning1 shared
Ling Yang1 shared
Matthew C Watson1 shared
Debra L Boyd Seale1 shared
Full investigator report
Get the verbatim findings behind Min Lu's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site